Last updated on October 2018

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function


Brief description of study

This is a randomized, double blind, active control study of PRX-102 (pegunigalsidase alfa) in Fabry disease patients with impaired renal function. Patients treated for approximately 1 year with agalsidase beta and on a stable dose for at least 6 months will be screened and then randomized to continue treatment with 1mg/kg agalsidase beta or to treatment with 1 mg/kg of PRX-102. The identity of the enzyme will be blinded to the patient and the investigator. Patients will receive intravenous infusions every two weeks. Patients will be randomized in a 2:1 ratio of PRX-102 to agalsidase beta. Randomization will be stratified by urinary protein to creatinine ratio (UPCR) of < or 1 g/g by spot urine sample. No more than 50% of the patients will be female.

Clinical Study Identifier: NCT02795676

Contact Investigators or Research Sites near you

Start Over

UAB Medicine

Birmingham, AL United States
  Connect »

Infusion Associates

Grand Rapids, MI United States
  Connect »

O+O Alpan LLC

Fairfax, VA United States
  Connect »

University of Washington

Seattle, WA United States
  Connect »

Medical College of Wisconsin

Milwaukee, WI United States
  Connect »

UZ Antwerpen

Edegem, Belgium
  Connect »

Addenbrooke's Hospital

Cambridge, United Kingdom
  Connect »

Arkansas Children's hospital

Little Rock, AR United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.